Dealogic has news this week that M&A dealmaking is getting hostile globally as the above graphic shows. In Europe, the volume jump was largely driven by Pfizer’s USD 122.6bn hostile bid for AstraZeneca announced on the 2nd May 2014. It is the third largest hostile M&A deal on record, according to dealogic.
As a result, Europe is the most targeted region for global hostile M&A transactions with USD 143.8bn due to six deals, up from just USD14.8bn in the same 2013 period. It is also the highest year to date volume since 2007, reports dealogic. North America follows with USD121.2bn in 2014 year to date, again the highest year to date level on record.